-
Management Board: Highlights of March 2023 meeting
Management Board: Highlights of March 2023 meeting
-
Management Board: Highlights of March 2023 meeting
Management Board: Highlights of March 2023 meeting
The Board received updates on the Agency’s extended mandate and the recent operational experience with the clinical trials information system
-
Highlights of the Safety Committee: March 2023
Highlights of the Safety Committee: March 2023
-
Highlights of the Safety Committee: March 2023
Highlights of the Safety Committee: March 2023
At its monthly meeting, EMA's safety committee, the PRAC, carried out its work to assess all aspects of risk management related to the use of medicines.
-
Human medicines: highlights of 2022
Human medicines: highlights of 2022
-
Human medicines: highlights of 2022
Human medicines: highlights of 2022
EMA recommended 89 human medicines for marketing authorisation in 2022. Check out our overview of key recommendations on the authorisation and safety monitoring of human medicines
-
Veterinary medicines: highlights of 2022
Veterinary medicines: highlights of 2022
-
Veterinary medicines: highlights of 2022
Veterinary medicines: highlights of 2022
EMA recommended 10 veterinary medicines for marketing authorisation in 2022. Check out our overview of key recommendations on the authorisation and safety monitoring of veterinary medicines
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal